Loading...
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
OBJECTIVE: Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and maintenance treatment in patients with moderate-to-severe Crohn's disease (CD). DESIGN: We conducted two randomised,...
Na minha lista:
| Udgivet i: | Gut |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532457/ https://ncbi.nlm.nih.gov/pubmed/28209624 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2016-312735 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|